Merck & Co (MSD) and Eisai’s combination therapies failed to meet the dual primary endpoints of progression-free survival ...
Both trials are ongoing and will report on overall survival at a subsequent analysis. Topline results were announced from two phase 3 trials evaluating combination regimens containing belzutifan ...
KEYTRUDA is currently approved as adjuvant monotherapy and in combination regimens for appropriate patients with RCC in the U.S., European Union (EU), Japan and other countries around the world. For ...
Merck & Co. Inc. MRK and Eisai on Tuesday announced results from the Phase 3 LITESPARK-012 trial of combination drugs for ...
Many medicines are available to treat kidney cancer. If one treatment doesn’t help or stops working, your health care provider may recommend another option. If you or a loved one has kidney cancer and ...
Source: Getty Images Avelumab plus axitinib did not improve overall survival in the overall population or in patients with PD-L1-positive disease. The median overall survival was 44.8 months in the ...
COPENHAGEN — First-line treatment of metastatic kidney cancer could be set for change, with new results showing that the oral tyrosine kinase inhibitor cabozantinib (Cabometyx, Exelixis) significantly ...
A review article in JCO Oncology Practice by Chen and colleagues provides a comprehensive update on management of advanced and metastatic renal cell carcinoma (RCC). Immune checkpoint inhibitors (ICIs ...
LOUISVILLE, Ky. -- Tumor outcomes and thrombus control in renal cell carcinoma (RCC) improved with perioperative treatment that included a targeted agent plus immunotherapy, a small retrospective ...
Merck and Eisai provide update on phase 3 LITESPARK-012 trial evaluating first-line combination treatments for certain patients with advanced RCC: Rahway, New Jersey Wednesday, Ap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results